Preeclampsia in Low and Middle Income Countries-Health Services Lessons Learned From the PRE-EMPT (PRE-Eclampsia-Eclampsia Monitoring, Prevention & Treatment) Project

Journal of Obstetrics and Gynaecology Canada

Volumn 34, Issue 10, 2012, Pages 917-926

  von Dadelszen, Peter ^a,b   Firoz, Tabassum ^a,b   Donnay, France ^c   Gordon, Rebecca ^a,b   Justus Hofmeyr, G ^d   Lalani, Shifana ^a   Payne, Beth A ^a,b   Roberts, James M ^e   Teela, Katherine C ^c   Vidler, Marianne ^a,b   Sawchuck, Diane ^a,b   Magee, Laura A ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c BILL AND MELINDA GATES FOUNDATION   (United States)

^d WALTER SISULU UNIVERSITY   (South Africa)

^e UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Global health; Hypertensive disorders of pregnancy; Preeclampsia

Indexed keywords

ANTIHYPERTENSIVE AGENT; CALCIUM; MAGNESIUM SULFATE;

ARTICLE; CALCIUM BALANCE; DEVELOPING COUNTRY; DIET SUPPLEMENTATION; DISEASE SEVERITY; HUMAN; MANAGED CARE; MATERNAL HYPERTENSION; PATIENT IDENTIFICATION; PATIENT MONITORING; PREECLAMPSIA; PREVENTIVE MEDICINE; PROTEINURIA; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK REDUCTION; ECLAMPSIA; FEMALE; HEALTH SERVICE; INCOME; PREGNANCY; REVIEW;

CALCIUM; DEVELOPING COUNTRIES; ECLAMPSIA; FEMALE; HUMANS; INCOME; MATERNAL HEALTH SERVICES; PRE-ECLAMPSIA; PREGNANCY; PROTEINURIA;

EID: 84899970143     PISSN: 17012163     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1701-2163(16)35405-6     Document Type: Article

References (77)

1. Steegers E.A., von Dadelszen P., Duvekot J.J., Pijnenborg R. Pre-eclampsia. Lancet 2010, 376:631-644.
2. Firoz T., Sanghvi H., Merialdi M., von Dadelszen P. Pre-eclampsia in low and middle income countries. Best Pract Res Clin Obstet Gynaecol 2011, 25:537-548.
3. Health Canada. Special report on maternal mortality and severe morbidity in Canada-enhanced surveillance: the path to prevention 2004, Minister of Public Works and Government Services Canada, Ottawa.
4. Khan K.S., Wojdyla D., Say L., Gulmezoglu A.M., Van Look P.F. WHO analysis of causes of maternal death: a systematic review. Lancet 2006, 367:1066-1074.
5. US Department of Health and Human Services, Health Resources and Services Administration. Women's Health USA 2011 2011, US Department of Health and Human Services, Rockville, MD.
6. Kaye D.K., Kakaire O., Osinde M.O. Systematic review of the magnitude and case fatality ratio for severe maternal morbidity in sub-Saharan Africa between 1995 and 2010. BMC Pregnancy Childbirth 2011, 11:65.
7. Tuncalp O., Hindin M.J., Souza J.P., Chou D., Say L. The prevalence of maternal near miss: a systematic review. BJOG 2012, 119:653-661.
8. Langer A., Villar J., Tell K., Kim T., Kennedy S. Reducing eclampsia-related deaths-a call to action. Lancet 2008, 371:705-706.
9. Belizan J.M., Villar J. The relationship between calcium intake and edema-, proteinuria, and hypertension-getosis: an hypothesis. Am J Clin Nutr 1980, 33:2202-2210.
10. Hamlin R.H. The prevention of eclampsia and pre-eclampsia. Lancet 1952, 1:64-68.
11. Hofmeyr G.J., Atallah A.N., Duley L. Calcium supplementation during pregnancy for preventing hypertensive disorders and related problems. Cochrane Database Syst Rev 2006, 3. CD001059.
12. Meads C.A., Cnossen J.S., Meher S., Juarez-Garcia A., ter Riet G., Duley L., et al. Methods of prediction and prevention of pre-eclampsia: systematic reviews of accuracy and effectiveness literature with economic modelling. Health Technol Assess 2008, 12(6):1-270. iii-iv.
13. Hofmeyr G.J., Mlokoti Z., Nikodem V.C., Mangesi L., Ferreira S., Singata M., et al. Calcium supplementation during pregnancy for preventing hypertensive disorders is not associated with changes in platelet count, urate, and urinary protein: a randomized control trial. Hypertens Pregnancy 2008, 27:299-304.
14. Villar J., Abdel-Aleem H., Merialdi M., Mathai M., Ali M., Zavaleta N., et al. World Health Organization randomized trial of calcium supplementation among low calcium intake pregnant women. Am J Obstet Gynecol 2006, 194:639-649.
15. Hofmeyr G.J., Duley L., Atallah A. Dietary calcium supplementation for prevention of pre-eclampsia and related problems: a systematic review and commentary. BJOG 2007, 114:933-943.
16. Li K., Kaaks R., Linseisen J., Rohrmann S. Associations of dietary calcium intake and calcium supplementation with myocardial infarction and stroke risk and overall cardiovascular mortality in the Heidelberg cohort of the European Prospective Investigation into Cancer and Nutrition study (EPIC-Heidelberg). Heart 2012, 98(12):920-925.
17. Raijmakers M.T., Dechend R., Poston L. Oxidative stress and preeclampsia: rationale for antioxidant clinical trials. Hypertension 2004, 44:374-980.
18. Poston L., Igosheva N., Mistry H.D., Seed P.T., Shennan A.H., Rana S., et al. Role of oxidative stress and antioxidant supplementation in pregnancy disorders. Am J Clin Nutr 2011, 94(Suppl 6):1980-1985.
19. Conde-Agudelo A., Romero R., Kusanovic J.P., Hassan S.S. Supplementation with vitamins C and E during pregnancy for the prevention of preeclampsia and other adverse maternal and perinatal outcomes: a systematic review and metaanalysis. Am J Obstet Gynecol 2011, 204:503-512.
20. World Health Organization. World Health Organization recommendations for prevention and treatment of pre-eclampsia and eclampsia 2011, World Health Organization, Geneva.
21. Institute of Medicine. Dietary reference intakes for calcium and vitamin D 2010, National Academy Press, Washington, DC.
22. Hofmeyr G.J., Mlokoti Z., Nikodem V.C., Mangesi L., Ferreira S., Singata M., et al. WHO Calcium Supplementation for the Prevention of Pre-eclampsia Trial Group. Calcium supplementation during pregnancy for preventing hypertensive disorders is not associated with changes in platelet count, urate, and urinary protein: a randomized control trial. Hypertens Pregnancy 2008, 27:299-304.
23. Jarjou L.M., Laskey M.A., Sawo Y., Goldberg G.R., Cole T.J., Prentice A. Effect of calcium supplementation in pregnancy on maternal bone outcomes in women with a low calcium intake. Am J Clin Nutr Aug 2010, 92(2):450-457.
24. Hofmeyr GJ, Novikova N, Singata M, Fawcus S, Oyebajo A, Munjanja S, et al. Protocol 11PRT/4028: Long term calcium supplementation in women at high risk of pre-eclampsia: a randomised, placebo-controlled trial (PACTR201105000267371). Available at: . Accessed August 15, 2012. http://www.thelancet.com/protocol-reviews/11PRT4028.
25. Abbott R.D., Curb J.D., Rodriguez B.L., Sharp D.S., Burchfiel C.M., Yano K. Effect of dietary calcium and milk consumption on risk of thromboembolic stroke in older middle-aged men. The Honolulu Heart Program. Stroke 1996, 27:813-818.
26. Iso H., Stampfer M.J., Manson J.E., Rexrode K., Hennekens C.H., Colditz G.A., et al. Prospective study of calcium, potassium, and magnesium intake and risk of stroke in women. Stroke 1999, 30:1772-1779.
27. Massey L.K. Dairy food consumption, blood pressure and stroke. J Nutr 2001, 131:1875-1878.
28. Menzies J., Magee L.A., Li J., MacNab Y.C., Yin R., Stuart H., et al. Preeclampsia Integrated Estimate of RiSk (PIERS) Study Group. Instituting surveillance guidelines and adverse outcomes in preeclampsia. Obstet Gynecol 2007, 110:121-127.
29. von Dadelszen P., Sawchuck D., McMaster R., Douglas M.J., Lee S.K., Saunders S., et al. The active implementation of pregnancy hypertension guidelines in British Columbia. Obstet Gynecol 2010, 116:659-666.
30. World Health Organization. mHealth: new horizons for health through mobile technologies: based on the findings of the second global survey on eHealth. Global observatory for eHealth series 2011, 3. WHO, Geneva.
31. United Nations Statistics Division. Millennium Development Goals indicators. New York: United Nations. Available at: . Accessed April 4, 2012. http://mdgs.un.org/unsd/mdg/default.aspx.
32. The Partnership for Maternal, Newborn and Child Health. International groups call for collaboration in use of mobile technology to reduce maternal and newborn mortality. Geneva: WHO; 2010. Available at:. Accessed April 10, 2012. http://www.who.int/pmnch/media/press_materials/pr/2010/20100624_ict_use/en/index.html.
33. Tamrat T., Kachnowski S. Special delivery: an analysis of mHealth in maternal and newborn health programs and their outcomes around the world. Matern Child Health J 2012, 16:1092-1101.
34. von Dadelszen P., Payne B., Li J., Ansermino J.M., Broughton P.F., Cote A.M., et al. Prediction of adverse maternal outcomes in pre-eclampsia: development and validation of the fullPIERS model. Lancet 2011, 377:219-227.
35. Firoz T., Magee L.A., Payne B.A., Menzies J.M., von Dadelszen P. The PIERS experience: research or quality improvement?. J Obstet Gynaecol Can 2012, 34:379-381.
36. Kozic J.R., Benton S.J., Hutcheon J.A., Payne B.A., Magee L.A., von Dadelszen P. Abnormal liver function tests as predictors of adverse maternal outcomes in women with preeclampsia. J Obstet Gynaecol Can 2011, 33:995-1004.
37. Laskin S., Payne B., Hutcheon J.A., Qu Z., Douglas M.J., Ford J., et al. The role of platelet counts in the assessment of inpatient women with preeclampsia. J Obstet Gynaecol Can 2011, 33:900-908.
38. Menzies J., Magee L.A., MacNab Y.C., Ansermino J.M., Li J., Douglas M.J., et al. Current CHS and NHBPEP criteria for severe preeclampsia do not uniformly predict adverse maternal or perinatal outcomes. Hypertens Pregnancy 2007, 26:447-462.
39. Millman A.L., Payne B., Qu Z., Douglas M.J., Hutcheon J.A., Lee T., et al. Oxygen saturation as a predictor of adverse maternal outcomes in women with preeclampsia. J Obstet Gynaecol Can 2011, 33:705-714.
40. Payne B., Magee L.A., von Dadelszen P. Assessment, surveillance and prognosis in pre-eclampsia. Best Pract Res Clin Obstet Gynaecol 2011, 25:449-462.
41. von Dadelszen P., Magee L.A., Roberts J.M. Subclassification of preeclampsia. Hypertens Pregnancy 2003, 22:143-148.
42. von Dadelszen P., Magee L.A., Devarakonda R.M., Hamilton T., Ainsworth L.M., Yin R., et al. The prediction of adverse maternal outcomes in preeclampsia. J Obstet Gynaecol Can 2004, 26:871-879.
43. von Dadelszen P., Menzies J., Magee L.A. The complications of hypertension in pregnancy. Minerva Med 2005, 96:287-302.
44. von Dadelszen P., Menzies J.M., Payne B., Magee L.A. Predicting adverse outcomes in women with severe pre-eclampsia. Semin Perinatol 2009, 33:152-157.
45. Yen T.W., Payne B., Qu Z., Hutcheon J.A., Lee T., Magee L.A., et al. Using clinical symptoms to predict adverse maternal and perinatal outcomes in women with preeclampsia: data from the PIERS (Pre-eclampsia Integrated Estimate of RiSk) study. J Obstet Gynaecol Can 2011, 33:803-809.
46. PRE-eclampsia Eclampsia Monitoring, Prevention & Treatment. The miniPIERS (Pre-eclampsia Integrated Estimate of RiSk) model. Available at: . Accessed April 10, 2012. http://pre-empt.cfri.ca/HOME.aspx.
47. Payne B., Hutcheon J.A., Qu Z., Haniff F., Bhutta Z., Biryabarema C., et al. MiniPIERS (Pre-eclampsia Integrated Estimate of RiSk): development of a clinical prediction model for use in low and middle income countries (LMICs). 18th World Congress of the International Society for the Study of Hypertension in Pregnancy, Geneva, Switzerland, July 2012.Pregn Hypertens 2012, 2(3):195-196.
48. Saving Lives at Birth. PIERS on the move: Pre-eclampsia Integrated Estimate of Risk assessment on a mobile phone. Available at: . Accessed April 10, 2012. http://savinglivesatbirth.net/summaries/37.
49. Roberts J.M., Bodnar L.M., Lain K.Y., Hubel C.A., Markovic N., Ness R.B., et al. Uric acid is as important as proteinuria in identifying fetal risk in women with gestational hypertension. Hypertension 2005, 46:1263-1269.
50. Cote A.M., Firoz T., Mattman A., Lam E.M., von Dadelszen P., Magee L.A. The 24-hour urine collection: gold standard or historical practice?. Am J Obstet Gynecol 2008, 199:625-626.
51. De Silva D.A., Halstead C., Cote A.M., Sabr Y., von Dadelszen P., Magee L.A. Unexpected random urinary protein:creatinine ratio results- insights from clinician-laboratory medicine collaboration. 18th World Congress of the International Society for the Study of Hypertension in Pregnancy, Geneva, Switzerland, July 2012. Pregn Hypertens 2012, 2:253.
52. De Silva D.A., Halstead C., Cote A.M., Sabr Y., von Dadelszen P., Magee L.A. Random urine albumin:creatinine ratio in high-risk pregnancy-is it clinically useful?. 18th World Congress of the International Society for the Study of Hypertension in Pregnancy,Geneva, Switzerland, July 2012. Pregn Hypertens 2012, 2:253-255.
53. Cote A.M., Brown M.A., Lam E., von Dadelszen P., Firoz T., Liston R.M., et al. Diagnostic accuracy of urinary spot protein:creatinine ratio for proteinuria in hypertensive pregnant women: systematic review. BMJ 2008, 336:1003-1006.
54. Payne B., Magee L.A., Cote A.M., Hutcheon J.A., Li J., Kyle P.M., et al. PIERS proteinuria: relationship with adverse maternal and perinatal outcome. J Obstet Gynaecol Can 2011, 33:588-597.
55. Lindheimer M.D., Kanter D. Interpreting abnormal proteinuria in pregnancy: the need for a more pathophysiological approach. Obstet Gynecol 2010, 115(2):365-375. Pt 1.
56. Centre for Maternal and Child Enquiries. Saving mothers' lives: reviewing maternal deaths to make motherhood safer: 2006-2008. The eighth report on confidential enquiries into maternal deaths in the United Kingdom. BJOG 2011, 118(Suppl 1).
57. The Confidential Enquiry into Maternal and Child Health (CEMACH). Saving mothers' lives: reviewing maternal deaths to makemotherhood safer-2003-2005. The seventh report on confidential enquiries into maternal deaths in the United Kingdom 2007, Confidential Enquiries into Maternal and Child Health, London. G. Lewis (Ed.).
58. Martin J.N., Thigpen B.D., Moore R.C., Rose C.H., Cushman J., May W. Stroke and severe preeclampsia and eclampsia: a paradigm shift focusing on systolic blood pressure. Obstet Gynecol 2005, 105:246-254.
59. National Committee for the Confidential Enquiries into Maternal Deaths. Saving mothers 2005-2007: fourth report on confidential enquiries into maternal deaths in South Africa 2011, National Department of Health, Pretoria.
60. Magee L.A., Helewa M., Moutquin J.M., von Dadelszen P. Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy. J Obstet Gynaecol Can 2008, 30(3):1-48. Suppl.
61. Reichenheim M.E., Zylbersztajn F., Moraes C.L., Lobato G. Severe acute obstetric morbidity (near-miss): a review of the relative use of its diagnostic indicators. Arch Gynecol Obstet 2009, 280:337-343.
62. Brown M.A., Lindheimer M.D., de Swiet M., Van Assche A., Moutquin J.M. The classification and diagnosis of the hypertensive disorders of pregnancy: statement from the International Society for the Study of Hypertension in Pregnancy (ISSHP). Hypertens Pregnancy 2001, 20(1):IX-XIV.
63. Lindheimer M.D., Taler S.J., Cunningham F.G. ASH position paper: hypertension in pregnancy. J Clin Hypertens (Greenwich) 2009, 11:214-225.
64. Lowe S.A., Brown M.A., Dekker G., Gatt S., McLintock C., McMahon L., et al. Guidelines for the management of the hypertensive disorders of pregnancy 2008. Society of Obstetric Medicine of Australia and New Zealand 2008.
65. Visintin C., Mugglestone M.A., Almerie M.Q., Nherera L.M., James D., Walkinshaw S. Guideline Development Group. Management of hypertensive disorders during pregnancy: summary of NICE guidance. BMJ 2010, 341. c2207.
66. World Health Organization. Priority medicines for mothers and children 2011. Geneva: WHO; March 2011. Available at: . Accessed April 10, 2012. http://www.who.int/medicines/publications/A4prioritymedicines.pdf.
67. McNeil D.G. Treatments: WHO lists priority medicines for children and pregnant women. New York Times 2011, March 28. Available at:, Accessed April 10, 2012. http://www.nytimes.com/2011/03/29/health/29global.html.
68. World Health Organization. WHO Model Lists of Essential Medicines 2011, WHO, Geneva, March. Available at:, Accessed April 10, 2012. http://www.who.int/medicines/publications/essentialmedicines/en.
69. Duley L., Gulmezoglu A.M., Henderson-Smart D.J., Walker G.J., Chou D. Magnesium sulphate and other anticonvulsants for women with pre-eclampsia. Cochrane Database Syst Rev 2010, (11). CD000025.
70. Duley L., Henderson-Smart D.J., Walker G.J., Chou D. Magnesium sulphate versus diazepam for eclampsia. Cochrane Database Syst Rev 2010, (12). CD00127.
71. Duley L., Henderson-Smart D.J., Chou D. Magnesium sulphate versus phenytoin for eclampsia. Cochrane Database Syst Rev 2010, (10). CD000128.
72. Duley L., Gulmezoglu A.M., Chou D. Magnesium sulphate versus lytic cocktail for eclampsia. Cochrane Database Syst Rev 2010, (9). CD002960.
73. Duley L., Matar H.E., Almerie M.Q., Hall D.R. Alternative magnesium sulphate regimens for women with pre-eclampsia and eclampsia. Cochrane Database Syst Rev 2010, (8). CD007388.
74. Magee L.A., Abalos E., von Dadelszen P., Sibai B., Walkinshaw S.A. Control of hypertension in pregnancy. Curr Hypertens Rep 2009, 11:429-436.
75. Mroczek W.J., Lee W.R., Davidov M.E. Effect of magnesium sulfate on cardiovascular hemodynamics. Angiology 1977, 28:720-724.
76. Magee L.A., Cham C., Waterman E.J., Ohlsson A., von Dadelszen P. Hydralazine for treatment of severe hypertension in pregnancy: meta-analysis. BMJ 2003, 327:955-960.
77. Magee L.A., Miremadi S., Li J., Cheng C., Ensom M.H., Carleton B., et al. Therapy with both magnesium sulfate and nifedipine does not increase the risk of serious magnesium-related maternal side effects in women with preeclampsia. Am J Obstet Gynecol 2005, 193:153-163.